Develops RV-001, an optogenetic gene therapy (chimeric rhodopsin via AAV) to restore vision in retinal diseases.
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Bridge RestoreVision raised 1.3 billion yen in a pre-Series B via J-KISS, with Astellas Venture Management, Ajinomoto and Shionogi joining. | $8.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.